drugset
drugset / Trial / NCT05658146

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

NCT05658146 ↗

Phase 1 Completed 95 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the effects on the single-dose drug levels of mavacamten in healthy participants.

Timeline

Start
2023-01-06
Primary completion
2023-07-05
Completion
2023-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule 5 mg —

Indications

No indication recorded.